YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Champions LS eqt Bruker


March 7, 2002

Bruker Daltonics Inc.
Frank H. Laukien, Ph.D.
President, CEO

New Tools for Proteomics

What is the history of your organization’s involvement in life sciences?
Laukien
: Bruker Daltonics has its roots in the affiliated Bruker BioSpin Group, which was founded in 1960. That company focused on magnetic resonance and in 1982 started the mass spectrometry division that would become Bruker Daltonics. We have seen and continue to see strong growth for the life sciences market for the next decade, causing us to make major company investments in this sector, adding capacity and expanding our life sciences development engineering staff.

What is your vision for the development of the life sciences market?
Laukien
: Now that we are in the post-genomic era, I am quite excited about all the life sciences possibilities developing in proteomics. We are placing particular emphasis here at Bruker Daltonics on proteomics tools development work for the next decade, especially on our leading-edge Proteineer integrated product line. Pharmacogenomics will continue to be another area of importance for us. Metabolomics is an emerging area that we are monitoring closely.

What organizational assets have you developed to serve this community?
Laukien
: Of particular importance is our strong core competency in mass spectrometry tools for the life sciences that we have built over the decades. We are the only “pure play” in mass spectrometry. Our large R&D engineering force of more than 150 engineers specializes in mass-spectrometry-based life science tools and is particularly successful in bringing out new cutting-edge products for the life sciences on a regular basis.

What products and services does your company provide to the life sciences market?
Laukien
: We continue to be a leading provider of innovative life science tools based on mass spectrometry. Our major investments in research and applied development allow us to design, manufacture, and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions, and government agencies. We have various technology platforms that integrate automated sample preparation and cleanup, advanced front-end AnchorChip™ MALDI targets, and API source technology with cutting-edge proprietary MALDI-Time of Flight, MALDI-TOF/TOF, Electrospray Ionization-TOF, ESI-Q-q-TOF, ESI-Ion Trap, and Fourier Transform mass analyzers, as well as analysis and bioinformatics software.
www.bdal.de

Return to main index page.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1





For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.